文献速递慢性肾脏病遗传性与小管间质肾病

总肾脏体积是常染色体显性多囊肾病肾功能下降和进展至终末期肾病的预后生物标志物

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · Kidney Int Rep · 2017-01-16

本研究纳入2355例有总肾脏体积(TKV)测量的常染色体显性多囊肾病(ADPKD)患者,采用多变量Cox模型评估年龄、TKV、身高调整TKV、eGFR、性别、种族和基因型的预后价值。结果显示TKV是预测eGFR下降30%和进展至终末期肾病(ESRD)的最重要预后指标,且TKV已被FDA和EMA正式认定为预后富集生物标志物。

要点

  • TKV是ADPKD患者eGFR下降30%和进展至ESRD的最重要预后指标。
  • 基线eGFR保留的40岁患者,TKV增大2倍和3倍时eGFR下降30%的风险比分别为1.86和2.68。
  • TKV已被FDA和EMA认定为预后富集生物标志物,可用于筛选高风险患者。

核心结论

  • TKV是ADPKD患者肾功能下降和进展至ESRD的重要预后生物标志物,且已被监管机构正式认定。

研究设计与样本

  • 观察性研究,纳入2355例有TKV测量的ADPKD患者,使用多变量Cox模型评估预后因素。

主要发现

  • 在基线eGFR保留与否的ADPKD患者中,TKV均是eGFR下降30%的最重要预后因素。
  • 40岁且基线eGFR为70 ml/min per 1.73 m2的患者,TKV增大2倍(600 vs. 1200 ml)时eGFR下降30%的风险比为1.86(95% CI 1.65-2.10)。
  • 同上人群,TKV增大3倍(600 vs. 1800 ml)时eGFR下降30%的风险比为2.68(95% CI 2.22-3.24)。
  • TKV增大2倍和3倍时进展至ESRD的风险比分别为1.72(95% CI 1.49-1.99)和2.36(95% CI 1.88-2.97)。

临床怎么用

  • 可将TKV作为ADPKD患者风险分层工具,识别肾功能进展高风险患者。
  • TKV可用于筛选适合纳入干预性临床试验的高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. TKV is a promising imaging biomarker for tracking and predicting the natural history of autosomal dominant polycystic kidney disease. The prognostic value of TKV was evaluated, in combination with age and eGFR, for the outcomes of 30% decline in eGFR and progression to ESRD. Observational data including 2355 patients with TKV measurements were available. METHODS: Multivariable Cox models were developed to assess the prognostic value of age, TKV, height-adjusted TKV, eGFR, sex, race, and genotype for the probability of a 30% decline in eGFR or ESRD. RESULTS: TKV was the most important prognostic term for 30% decline in eGFR in autosomal dominant polycystic kidney disease patients with and without preserved baseline eGFR. For a 40-year-old subject with preserved eGFR (70 ml/min per 1.73 m2), the adjusted hazard ratios for a 30% decline in eGFR were 1.86 (95% CI, 1.65-2.10) for a 2-fold larger TKV (600 vs. 1200 ml) and 2.68 (95% CI, 2.22-3.24) for a 3-fold larger TKV (600 vs. 1800 ml), respectively. Hazard ratios for progression to ESRD for 2- and 3-fold larger TKV were 1.72 (95% CI, 1.49-1.99) and 2.36 (95% CI, 1.88-2.97), respectively. DISCUSSION: The capability to predict 30% decline in eGFR is a novel aspect of this study. TKV was formally qualified, both by FDA and EMA, as a prognostic enrichment biomarker for selecting patients at high risk for a progressive decline in renal function for inclusion in interventional clinical trials.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Perrone RD, Mouksassi MS, Romero K, et al. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017. PMID: 29142971. doi:10.1016/j.ekir.2017.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。